Prevalence and trend of biopsy-proven IgA nephropathy in China: a systematic review

被引:0
|
作者
Xu, Lichen [1 ,2 ]
Wu, Changwei [1 ,2 ]
Li, Guisen [1 ,2 ]
机构
[1] Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Sch Med, Dept Nephrol, 32,West 2nd Duan,1st Circle Rd, Chengdu 610072, Sichuan, Peoples R China
[2] Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Inst Nephrol, Sch Med, 32,West 2nd Duan,1st Circle Rd, Chengdu 610072, Sichuan, Peoples R China
基金
中国国家自然科学基金;
关键词
IgA nephropathy; Prevalence; Trend; Distribution; Systemic review; PRIMARY GLOMERULONEPHRITIS; RENAL BIOPSY; GLOMERULAR-DISEASE; EPIDEMIOLOGY; SPECTRUM; EXPOSURE;
D O I
10.1007/s40620-025-02261-1
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background IgA nephropathy (IgAN) is one of the most common primary glomerulonephritis worldwide, and its distribution varies significantly in different regions. The prevalence and trend of its changes in different regions of China are still unclear. Therefore, this study aims to analyze kidney biopsy data to summarize the prevalence and trend of IgAN in different regions in China. Methods Through a systematic electronic search of PubMed, Embase, China National Knowledge Infrastructure (CNKI), Chinese Biomedical Literature Database (SinoMed), Cochrane Library, and Wanfang databases from inception to March 1, 2023. Kidney biopsy data from the different provinces, municipalities and autonomous regions were recorded and analyzed. Results Data concerning a total of 143,176 patients with primary glomerulonephritis in 34 provinces of China were extracted from the reported kidney biopsy data and included in the final analysis set, of which 39.73% were IgAN (56,886 cases). The proportions of male and female patients were 58.67% and 41.33%, respectively. The prevalence of IgAN patients was higher in economically developed provinces and municipalities. The weighted average prevalence before 2010 and after 2010 was 40.45% and 37.97%, respectively. Conclusions IgAN remains the most common biopsy-proven primary glomerulonephritis in China. The prevalence of IgAN was 39.73% in China, and it was higher in developed provinces and municipalities than in other areas. The weighted average prevalence of IgAN in China decreased slightly after 2010.
引用
收藏
页数:8
相关论文
共 50 条
  • [31] Prevalence and immunopathologic characteristics of seropositive and seronegative hepatitis B virus-associated membranous nephropathy: a retrospective study of 420 biopsy-proven cases
    Lu, Haitao
    Xu, Qianqian
    Zou, Guming
    Gao, Hongmei
    Yang, Yue
    Li, Wenge
    Zhuo, Li
    RENAL FAILURE, 2024, 46 (01)
  • [32] Long-Term Outcomes of Japanese Type 2 Diabetic Patients With Biopsy-Proven Diabetic Nephropathy
    Shimizu, Miho
    Furuichi, Kengo
    Toyama, Tadashi
    Kitajima, Shinji
    Hara, Akinori
    Kitagawa, Kiyoki
    Iwata, Yasunori
    Sakai, Norihiko
    Takamura, Toshinari
    Yoshimura, Mitsuhiro
    Yokoyama, Hitoshi
    Kaneko, Shuichi
    Wada, Takashi
    DIABETES CARE, 2013, 36 (11) : 3655 - 3662
  • [33] Changes in the spectrum of biopsy-proven renal diseases over 11 years: a single-center study in China
    Wang, Yujia
    Zhang, Liyin
    Yuan, Li
    Xie, Qionghong
    Liu, Shaojun
    Hao, Chuan-ming
    RENAL FAILURE, 2024, 46 (02)
  • [34] Decreasing trend in the incidence and prevalence of dementia: a systematic review
    Mayer, Flavia
    Remoli, Giulia
    Bacigalupo, Ilaria
    Palazzesi, Ilaria
    Piscopo, Paola
    Bellomo, Guido
    Canevelli, Marco
    Corbo, Massimo
    Vanacore, Nicola
    Lacorte, Eleonora
    MINERVA MEDICA, 2021, 112 (04) : 430 - 440
  • [35] Mycophenolate mofetil in the treatment of IgA nephropathy: a systematic review
    Tan, C. H. R.
    Loh, P. T.
    Yang, W. S.
    Chan, C. M.
    SINGAPORE MEDICAL JOURNAL, 2008, 49 (10) : 780 - 785
  • [36] Analysis of serum metabolomics among biopsy-proven diabetic nephropathy, type 2 diabetes mellitus and healthy controls
    Tao, Sibei
    Zheng, Wen
    Liu, Yuan
    Li, Ling
    Li, Lingzhi
    Ren, Qian
    Shi, Min
    Liu, Jing
    Jiang, Jing
    Ma, Huichao
    Huang, Zhuo
    Xia, Zijing
    Pan, Jing
    Wei, Tiantian
    Wang, Yan
    Li, Peiyun
    Lan, Tian
    Ma, Liang
    Fu, Ping
    RSC ADVANCES, 2019, 9 (33) : 18713 - 18719
  • [37] Racial/ethnic differences in fibrosis prevalence and progression in biopsy-proven steatosis: A focus on the Asian American population
    Kim, Rebecca G.
    Chu, Janet N.
    Vittinghoff, Eric
    Deng, Jasmine
    Reaso, Jewel N.
    Grenert, James P.
    Khalili, Mandana
    HEPATOLOGY COMMUNICATIONS, 2022, 6 (11) : 3024 - 3035
  • [38] The clinical course of biopsy-proven demyelinating disease and comparison with a population-based MS prevalence cohort
    Pittock, S
    McClelland, R
    Achenbach, S
    Bitsch, A
    Bruck, W
    Lassmann, H
    Rodriguez, M
    Parisi, J
    Scheithauer, B
    Lucchinetti, C
    MULTIPLE SCLEROSIS, 2004, 10 (01):
  • [39] Nomogram analysis of the influencing factors of rapid renal decline in patients with biopsy-proven diabetic nephropathy in type 2 diabetes
    Ma, Yan
    Ren, Yuqian
    Hui, Di
    Zhang, Lihua
    Jiao, Chengfeng
    Xie, Honglang
    CLINICAL NEPHROLOGY, 2023, 99 (06) : 274 - 282
  • [40] Clinicopathological spectrum of biopsy-proven renal diseases of patients at a single center in Sri Lanka: a cross sectional retrospective review
    Muthukuda, Chanaka
    Suriyakumara, Vindika
    Sosai, Cherine
    Samarathunga, Thilina
    Laxman, Maithili
    Marasinghe, Arjuna
    BMC NEPHROLOGY, 2023, 24 (01)